HTGF invests in hepatitis drug project

The drug, Myrcludex B, will be developed in a joint project between new Russian company Hepatera LLC and High-Tech Gründerfonds' portfolio company MYR GmbH, which holds the product rights for the drug.

Both companies will receive funding concurrently.

The idea for Myrcludex B was developed by the French National Institute of Health and Medical Research (INSERM) and University of Heidelberg in Germany.

Under MYR, with an initial €500.000 investment from High-Tech Gründerfonds, the drug was taken through the first phase of clinical testing in 2011.

The company hopes that the joint approach will enable the drug to move to a "proof of concept" trial within a few months.

Company
Hepatera was founded in Russia in September 2011 as a private biotech company. In December 2011 it became a resident at Skolkovo Innovation Center, a government-backed private initiative located close to Moscow.

The company specialises in developing liver disease-related drugs.

MYR was founded in 2010 and is situated in Burgwedel near Hannover.

People
Dmitri Popov is managing partner at Maxwell Biotech Venture Fund. Bernd Goergen is senior investment manager at High-Tech Gründerfonds.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• DACH
• Early-stage
• Healthcare
• High-Tech Gründerfonds